Boston Scientific Announces New Clinical Data to be Presented at ACC 2012 on the Market-Leading PROMUS Element™ Stent

NATICK, Mass., March 20, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the American College of Cardiology/i2 Summit, March 24-27 in Chicago.

"Two-year results from the PLATINUM Workhorse clinical trial will provide important follow-up data on our next-generation PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent," said Keith D. Dawkins, M.D., Global Chief Medical Officer for Boston Scientific.  "Additional analysis from the PLATINUM and PERSEUS trials will provide further insight into the performance of our platinum chromium stent platform."

Schedule of Events (All times are CST, with events to be held at the McCormick Place Convention Center)

Saturday, March 24

  • PROTECT AF Quality of Life Assessment.  David Holmes, M.D., the Global Principal Investigator of the PROTECT AF clinical trial, will present data assessing the Quality of Life of 527 patients that received the WATCHMAN® left atrial appendage closure device versus those randomized to warfarin.  The PROTECT AF trial demonstrated the WATCHMAN device was non-inferior to long-term warfarin therapy for stroke prevention.  Results will be presented starting at 9:30 a.m. during a poster session in Hall A.

Sunday, March 25

  • PLATINUM/PERSEUS Longitudinal Stent Deformation Analysis.  Dean Kereiakes, M.D., the Principal Investigator of the PERSEUS clinical program, will present the largest systematic independent core laboratory analysis to date evaluating the incidence of longitudinal stent deformation in 2,403 patients treated with single stents in the PLATINUM and PERSEUS randomized clinical trials.  Outcomes will compare the PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System to the PROMUS® (XIENCE V®) Everolimus-Eluting Coronary Stent System and the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System (TAXUS® Element™) to the TAXUS Express® Paclitaxel-Eluting Coronary Stent System.  Results will be presented at 11:00 a.m. during an oral presentation in Room S101a.  The Company plans to issue a press release announcing study results at this time.
  • PLATINUM Workhorse two-year outcomes.  Gregg Stone, M.D., the Global Principal Investigator of the PLATINUM clinical program, will present two-year results from the PLATINUM Workhorse trial.  The randomized, controlled trial enrolled 1,530 patients at 132 sites worldwide and compares the PROMUS Element Everolimus-Eluting Platinum Chromium Coronary Stent System to the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent System.  Results will be presented at 11:45 a.m. during an oral presentation in Room S101a.  The Company plans to issue a press release announcing trial results at this time.

Monday, March 26

  • SMART-AV Impact of Electrical Delay on AV Optimization.  Michael Gold, M.D., will present results on the impact of left ventricular electrical delay (QLV) on the benefit of SmartDelay™ optimization during cardiac resynchronization therapy.  SMART-AV is a randomized three-armed trial designed to investigate the effects of optimizing AV delay timing in heart failure patients receiving CRT-D therapy.  Results will be presented during a moderated poster session starting at 9:30 a.m. in Hall A.

Boston Scientific will present its latest cardiology, rhythm and vascular products at booth #3063 in the Exhibit Hall. 

In the U.S., the WATCHMAN device is an investigational device, limited by applicable law to investigational use and not available for sale.  XIENCE V is a trademark of the Abbott Laboratories group of companies.  The PROMUS Stent is a private-labeled XIENCE V Stent manufactured by Abbott and distributed by Boston Scientific.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit:  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

Eric Olson
336-293-4393 (office)
Media Relations
Boston Scientific Corporation                      

Sean Findlen
617-520-7268  (office)
Media Relations
Weber Shandwick

Sean Wirtjes
508-652-5305 (office)
Investor Relations
Boston Scientific Corporation

SOURCE Boston Scientific Corporation